Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 12, Issue 1, 2007, Pages 36-43

  Mykytsey, Andrew ^a   Bauman, Jerry L ^b   Razminia, Mansour ^a   Zheutlin, Terry ^a   Wang, Ted ^a   Saleem, Mohammad ^a   Leal, Sergio ^a   Kehoe, Richard F ^a  

^a ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Dofetilide; Paroxysmal atrial fibrillation; Proarrhythmia; Symptomatic improvement

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; FLECAINIDE; PROPAFENONE; SOTALOL; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT VENTRICLE FUNCTION; HEART PROARRHYTHMIA; HOSPITAL DISCHARGE; HUMAN; MALE; MEDICAL RECORD REVIEW; MONOMORPHIC VENTRICULAR TACHYCARDIA; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; QT PROLONGATION; VALVULAR HEART DISEASE;

ADULT; AGED; AGED, 80 AND OVER; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FLECAINIDE; FOLLOW-UP STUDIES; HUMANS; INPATIENTS; LONG QT SYNDROME; MALE; MIDDLE AGED; PHENETHYLAMINES; PROPAFENONE; RECURRENCE; SOTALOL; SULFONAMIDES; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; WITHHOLDING TREATMENT;

EID: 34247630226     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248407299272     Document Type: Article

References (24)

1. Tsang Tsm, Petty GW, Barnes ME, et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol. 2003 ; 42: 93-100.
2. Levy S., Camm AJ, Saksena S., et al. International consensus on nomenclature and classification of atrial fibrillation: a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace. 2003 ; 5: 119-122.
3. Davidson E., Weinberger I., Rotenberg Z., Fuchs J., Agmon J. Atrial fibrillation: causes and time of onset. Arch Intern Med. 1989 ; 149: 457-459.
4. Kannel WB, Abbott RD, Savage DD, McNamara PM Coronary heart disease and atrial fibrillation. The Framingham study. Am Heart J. 1983 ; 106: 389-396.
5. Phillips SJ, Whisnant JP, O'Fallon WM, Frye RL Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc. 1990 ; 65: 344-351.
6. Carmeliet E. Voltage and time dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther. 1992 ; 262: 809-817.
7. Mounsey JP, DiMarco JP Dofetilide. Circulation. 2000 ; 102: 2665-2670.
8. Singh S., Zoble RG, Yellen L., et al. Efficacy and safety of oral dofetilide in converting and maintaining sinus rhythm in patients with chronic atrial fibrillation or a flutter. The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study. Circulation. 2000 ; 102: 2385-2390.
9. Falk RH, Pollak A., Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol. 1997 ; 29: 385-390.
10. Pedersen OD, Bagger H., Keller N., Marchant B., Kober L., Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation. 2001 ; 104: 292-296.
11. Torp-Pedersen C., Moller M., Bloch-Thomsen P., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999 ; 341: 857-865.
12. Kober L., Thompsen Peb, Moller M., et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet. 2000 ; 356: 2052-2058.
13. Fuster V., Ryden LE, Cannom DS, et al. ACC/AHA/ ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006 ; 114: 700-752.
14. Dofetilide [package insert]. New London, CT: Pfizer Laboratories ; 1999.
15. Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000 ; 342: 913-920.
16. Southworth MR, Zarembski D., Viana M., Bauman JL Sotalol versus quinidine for the maintenance of sinus rhythm after direct-current cardioversion of atrial fibrillation. Am J Cardiol. 1999 ; 83: 1629-1632.
17. Greenbaum RA, Campbell TJ, Channer KS, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation and Dofetilide) Study [abstract]. Circulation. 1998 ; 17 (suppl): 1633.
18. Prystowsky EN, Freeland SR, Freeland R., et al. Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2003 ; 14: S287 - S290.
19. Li D., Benardeau A., Nattel S. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation. 2000 ; 102: 104-112.
20. Mazur A., Anderson ME, Bonney S., Roden DM Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator based evaluation. J Am Coll Cardiol. 2001 ; 37: 1100-1105.
21. Reiffel JA Atypical proarrhythmia with dofetilide: monomorphic ventricular tachycardia and exercise-induced torsades de pointes. Pacing Clin Electrophysiol. 2005 ; 28: 877-879.
22. McClellan KJ, Markham A. Dofetilide: a review of its use in atrial fibrillation and atrial flutter. Drugs. 1999 ; 58: 1043-1059.
23. Brembilla-Perrot B., Houriez P., Beurrier D., Claudon O., Terrier de la Chaise A., Louis P. Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiarrhythmic drugs for atrial tachyarrhythmias. Int J Cardiol. 2001 ; 80: 7-15.
24. Falk HR Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med. 1992 ; 117: 141-150.